Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,911.20 | 2.40 | -0.03% |
| CAC 40 | 8,150.64 | 64.59 | 0.80% |
| DAX 40 | 24,199.50 | 238.91 | 1.00% |
| Dow JONES (US) | 47,951.85 | 65.88 | 0.14% |
| FTSE 100 | 9,837.77 | 63.45 | 0.65% |
| HKSE | 25,570.32 | 72.19 | 0.28% |
| NASDAQ | 23,006.36 | 313.04 | 1.38% |
| Nikkei 225 | 49,491.28 | 489.78 | 1.00% |
| NZX 50 Index | 13,373.10 | 116.33 | 0.88% |
| S&P 500 | 6,774.76 | 53.33 | 0.79% |
| S&P/ASX 200 | 8,619.30 | 2.20 | -0.03% |
| SSE Composite Index | 3,878.01 | 1.64 | 0.04% |